Skip to main content
. 2016 Jul 10;2016:9817606. doi: 10.1155/2016/9817606

Table 2.

Complications, response rate, and survival by treatment regimen.

RCHOP RChOP RCOP p value
N (%) 53 (100) 48 (100) 40 (100)

Complications of treatment

Infections
 None 18 (33.96) 14 (29.17) 23 (57.5) 0.09
 Ambulatory treated 15 (22.64) 12 (25.0) 10 (25)
 Febrile neutropenia (FN) 12 (22.64) 11 (22.92) 4 (10)
 Other than FN, requiring hospitalization 8 (15.09) 11 (22.92) 3 (7.5)

Myelosuppression
 None 36 (67.92) 30 (62.5) 26 (65) 0.94
 No transfusion required 6 (11.32) 8 (16.67) 5 (12.5)
 Required transfusion 11 (20.75) 10 (20.83) 9 (22.5)

Other complications (G III-IV)
 None 28 (52.83) 17 (35.42) 24 (60) 0.359
 Pain 3 (5.66) 4 (8.33) 2 (5)
 2nd malignancy 0 1 (2.08) 0
 Neuropathy 1 (1.89) 5 (10.42) 2 (5)
 Lung 0 1 (2.08) 0
 Thrombosis 1 (1.89) 3 (6.25) 0
 Cardiovascular 8 (15.09) 5 (10.42) 6 (15)
 Gastrointestinal 8 (15.09) 5 (10.42) 6 (15)
 Renal 4 (7.55) 7 (14.58) 2 (5)

Required radiotherapy 22 (41.51) 17 (35.42) 18 (45) 0.065

Response
 Complete 35 (66.04) 30 (62.5) 21 (52.5)
 Partial 6 (11.32) 3 (6.25) 3 (7.5) 0.418
 Stable disease 0 0 1 (2.5)
 Progressive disease 2 (3.77) 6 (12.5) 3 (7.5)
 Not evaluated 10 (18.87) 9 (18.75) 12 (30)

Relapsed 6 (11.32) 6 (12.5) 7 (17.5) 0.668

Mean disease-free survival (95% IC) 34.72 (29.54–39.89) 27.77 (22.28–33.25) 24.99 (18.9–31.09) >0.05

Mean overall survival (95% IC) 35.8 (30.56–41.05) 27.69 (22.18–33.2) 44.29 (32.65–55.93) >0.05

Restricted mean.